Prostate cancer is the second leading cause of death from cancer in men, particularly those over 65. It develops in the prostate gland and can spread to other parts of the body if left untreated. In the United States, about 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Early detection is crucial for improving treatment outcomes and survival rates. Regular screening can help identify the disease in its early stages when it is most treatable.
This article aims to provide a comprehensive overview of prostate cancer screening methods. Our goal is to inform the public about the importance of early screening and what the best choice might be.
Prostate cancer has the highest incidence rate and the second-highest mortality rate among cancers in American men. The overall prognosis for prostate cancer is generally favorable, especially when detected early. The 5-year relative survival rate is nearly 100 percent, the 10-year rate is 98 percent, and the 15-year rate is 95 percent.
Early detection plays a crucial role in prostate cancer management. Early detection improves survival rates, allowing for more effective treatment options, often with less invasive procedures. This can help preserve urinary and sexual function, which are common concerns for prostate cancer patients. Detecting prostate cancer early allows the patient access to treatments with more manageable side effects, improving their overall quality of life.
The Prostate-Specific Antigen (PSA) test measures the level of PSA in a man’s blood. PSA is a protein produced by both normal and cancerous cells in the prostate. It is primarily used to screen for prostate cancer and monitor its progression. A blood sample is taken and sent to a laboratory for analysis, with the results reported as nanograms of PSA per ml (ng/ ml) of blood.
The US Preventive Services Task Force (USPSTF) recommends that men aged 55-69 discuss PSA screening with their healthcare provider. The American Urological Association suggests that the interval should be 2 or more years to reduce the harm of screening.
PSA testing does have some limitations; these can include false positives and negatives, an inability to differentiate between aggressive and slow-growing cancers, overdiagnosis, and overtreatment.
While there is no definitive cutoff, PSA levels below 3.0 ng/ml are traditionally considered normal. However, cancer can occur with lower levels, and higher levels don’t always indicate cancer. Some guidelines suggest different PSA thresholds for different age groups. For example, a PSA level above 2.5 ng/ml might be concerning for men aged 40-49, while for men 70-79, the threshold might be 6.5 ng/ml.
PSA levels can be influenced by various factors, including age, prostate size, inflammation, infection, recent ejaculations, vigorous exercise, and certain medications.
If PSA levels are high, additional tests and procedures may be recommended:
The digital rectal exam (DRE) is a physical examination procedure used to detect abnormalities of the prostate gland. During a DRE, a trained healthcare professional inserts a gloved, lubricated finger into the rectum to feel the prostate gland through the rectal wall. The exam typically takes only a few minutes to complete and is often used in combination with the PSA blood test for prostate cancer screening with 76.9 percent accuracy.
The DRE is not particularly sensitive or specific for detecting prostate cancer. It correctly identifies 51 percent of men who actually have prostate cancer and incorrectly suggests cancer in 41 percent of men who are actually cancer-free. Furthermore, some men may find the DRE uncomfortable or embarrassing.
While both computed tomography (CT) and magnetic resonance imaging (MRI) are used in prostate cancer, they have different roles. MRI scans can detect potentially serious prostate cancers that may be missed by PSA tests alone and can help determine whether a biopsy is needed, potentially sparing up to one-third of men from undergoing invasive biopsies when results indicate nothing suspicious.
CT scans are not typically used as a primary tool for prostate cancer screening due to their limitations in soft tissue characterization and the associated high radiation dose. However, they do play a role in certain aspects of prostate cancer management.
CT scans are useful in staging prostate cancer, particularly to determine if the cancer has spread to nearby lymph nodes or other organs. They are often used in conjunction with other tests like PSA levels to decide on further imaging or treatment options.
The main risk factors for prostate cancer include:
Lifestyle factors can also play a role in cancer risk. Being overweight or obese increases the risk of advanced or metastatic prostate cancer. Some studies suggest that high dairy consumption and high calcium intake may slightly increase the risk of prostate cancer. Certain occupational exposures, such as pesticides or firefighting, may also increase the risk. While some of these factors are unavoidable, regular exercise and a good diet can help reduce your risk of prostate cancer.
The American Cancer Society (ACS) suggests discussing screening at 50 for men with average risk, at 45 for men at high risk, and at age 40 for men at an even higher risk. If no prostate cancer is found after screening, the ACS recommends that future screenings may be conducted every 2 years for men with PSA levels below 2.5 ng/ml, or annually for those with higher levels.
For men aged 55-69, the USPSTF recommends individual decision-making about prostate cancer screening after discussing potential benefits and harms with a clinician. For men aged 70 and over, the USPSTF recommends against PSA screening.
The American Urological Association and Society of Urologic Oncology (SUO) recommend offering baseline PSA testing to men between the ages of 45 and 50 and prostate cancer screening beginning at age 40 to 45 for people at increased risk. For men aged 50-69, the SUO advises offering regular prostate cancer screening every 2-4 years. Furthermore, the SUO suggested personalizing the re-screening interval or discontinuing screening based on individual factors and shared decision-making.
Prostate cancer, the second leading cause of cancer death among men, is best managed through early detection and regular screening. Key methods include PSA testing and digital rectal exams despite their limitations. Risk factors such as age, ethnicity, family history, and lifestyle should guide screening decisions. Given the high survival rates with early diagnosis, it's crucial for men, especially those over 50 or at higher risk, to discuss screening options with their healthcare providers. Early detection not only improves treatment outcomes but also enhances quality of life, making regular screening a vital tool in combating prostate cancer.
If you want to be proactive about your health, why not find out your risk for cancer and book an Ezra full-body MRI? Our annual scan catches potential cancer earlier, leveraging AI through the screening process to make it more efficient, affordable, and faster.
